Doliver Advisors’s ImmunityBio IBRX Stock Holding History

Doliver Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$876K	Buy	100,000 +50,000	+100%	+$378K	0.2%	83
2026 Q1	$384K	Buy	+50,000	New	+$342K	0.09%	136

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Doliver Advisors's IBRX Position: Q2 2026 in Review

Doliver Advisors increased its ImmunityBio (IBRX) stake by 100% in Q2 2026, buying an estimated $378K and bringing the position to 100,000 shares worth $876K. The position accounts for 0.2% of the portfolio, ranked #83.

Doliver Advisors first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Doliver Advisors held 100,000 shares of ImmunityBio worth $876K as of Q2 2026.
Doliver Advisors bought 50,000 ImmunityBio shares in Q2 2026, an estimated $378K.
ImmunityBio made up 0.2% of Doliver Advisors's portfolio in Q2 2026, its #83 holding.
Doliver Advisors first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Doliver Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.